8 Current news of Amorfix Life Sciences
rss10-29-2009
Amorfix Life Sciences announced it has detected prions in blood from non-human primates that were orally-infected with BSE and developed a primate version of vCJD. "Amorfix was able to obtain only a limited number of these very rare primate samples. Considering the small number of samples ...
06-25-2009
Amorfix Life Sciences announced it has tested 20,000 blood donations in France using its EP-vCJD™ blood screening test as part of a large-scale study to demonstrate the feasibility of routine testing of blood donations for vCJD (variant Creutzfeldt-Jakob disease). At the UK specification of a ...
06-26-2008
Amorfix Life Sciences announced that its diagnostic test for the presence of aggregated Abeta in Alzheimer's disease is ready to be applied to patient samples. The company has adapted its test to specifically detect aggregated Abeta protein (amyloid) in femtogram quantities from an ...
05-05-2008
Amorfix Life Sciences Ltd. announced the detection of endogenous prions in the blood plasma of asymptomatic scrapie infected sheep. The company had previously reported detecting symptomatic sheep which was a requirement for testing of human vCJD in the United Kingdom. "Identification of ...
09-07-2006
Amorfix Life Sciences Inc. and the Ontario Genomics Institute (OGI) announced the achievement of the technical milestone of demonstrating that Amorfix's Epitope Protection (EP) technology is able to detect protected sites within Abeta amyloid aggregates which are formed in Alzheimer's ...
06-23-2006
Amorfix Life Sciences Ltd. announced it had completed the analysis of the international reference blinded panels of human blood samples spiked with prions from variant Creutzfeldt-Jakob Disease (vCJD) patients which were provided by the UK government. "Our excellent results from the blinded ...
02-02-2006
Amorfix Life Sciences Inc. and the Ontario Genomics Institute (OGI) announced they are entering into a partnership to develop a blood test for Alzheimer's disease, EP-AD(TM), based upon Amorfix's patent-pending Epitope Protection technology. OGI will assist Amorfix in accelerating its program ...
01-30-2006
Amorfix Life Sciences Ltd. reported that it has completed the first step towards adapting its patent pending Epitope Protection technology to detecting bovine prions, the infectious aggregated misfolded proteins that cause BSE. This advance was accomplished by identifying two epitopes (or ...
